Home/Filings/4/0000899243-20-019899
4//SEC Filing

Polaris Partners GP VIII, L.L.C. 4

Accession 0000899243-20-019899

CIK 0001807901other

Filed

Jul 20, 8:00 PM ET

Accepted

Jul 21, 7:51 PM ET

Size

28.0 KB

Accession

0000899243-20-019899

Insider Transaction Report

Form 4
Period: 2020-07-21
Transactions
  • Conversion

    Common Stock

    2020-07-21+9,736109,373 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-07-21+2,783,8922,783,892 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-07-2149,6520 total(indirect: See footnote)
    Common Stock (9,736 underlying)
  • Purchase

    Common Stock

    2020-07-21$18.00/sh+34,863$627,5343,090,801 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-07-21+272,0463,055,938 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2020-07-2114,196,1520 total(indirect: See footnote)
    Common Stock (2,783,892 underlying)
  • Conversion

    Series B Preferred Stock

    2020-07-211,387,2680 total(indirect: See footnote)
    Common Stock (272,046 underlying)
  • Conversion

    Common Stock

    2020-07-21+99,63799,637 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-21$18.00/sh+1,248$22,464110,621 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2020-07-21508,0900 total(indirect: See footnote)
    Common Stock (99,637 underlying)
Transactions
  • Conversion

    Common Stock

    2020-07-21+99,63799,637 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-21$18.00/sh+34,863$627,5343,090,801 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-07-211,387,2680 total(indirect: See footnote)
    Common Stock (272,046 underlying)
  • Conversion

    Series A Preferred Stock

    2020-07-21508,0900 total(indirect: See footnote)
    Common Stock (99,637 underlying)
  • Purchase

    Common Stock

    2020-07-21$18.00/sh+1,248$22,464110,621 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-07-21+272,0463,055,938 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-07-21+9,736109,373 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-07-21+2,783,8922,783,892 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2020-07-2114,196,1520 total(indirect: See footnote)
    Common Stock (2,783,892 underlying)
  • Conversion

    Series B Preferred Stock

    2020-07-2149,6520 total(indirect: See footnote)
    Common Stock (9,736 underlying)
Transactions
  • Conversion

    Common Stock

    2020-07-21+9,736109,373 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2020-07-2114,196,1520 total(indirect: See footnote)
    Common Stock (2,783,892 underlying)
  • Conversion

    Common Stock

    2020-07-21+99,63799,637 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-07-2149,6520 total(indirect: See footnote)
    Common Stock (9,736 underlying)
  • Conversion

    Common Stock

    2020-07-21+2,783,8922,783,892 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-07-21+272,0463,055,938 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-07-211,387,2680 total(indirect: See footnote)
    Common Stock (272,046 underlying)
  • Purchase

    Common Stock

    2020-07-21$18.00/sh+34,863$627,5343,090,801 total(indirect: See footnote)
  • Purchase

    Common Stock

    2020-07-21$18.00/sh+1,248$22,464110,621 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2020-07-21508,0900 total(indirect: See footnote)
    Common Stock (99,637 underlying)
Footnotes (3)
  • [F1]The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  • [F2]The reportable securities are owned directly by Polaris Partners VIII, L.P. ("PP VIII"). Polaris Partners GP VIII, L.L.C. ("PPGP VIII") is the general partner of PP VIII. Each of David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII (collectively, the "Managing Members"). Each of the Managing Members may be deemed to have shared voting and dispositive power over the shares held by PP VIII. Each of PPGP VIII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  • [F3]The reportable securities are owned directly by Polaris Entrepreneurs' Fund VIII, L.P. ("PEF VIII"). PPGP VIII is the general partner of PEF VIII. Each of the Managing Members may be deemed to have shared voting and dispositive power over the shares held by PEF VIII. Each of PPGP VIII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Issuer

Pandion Therapeutics, Inc.

CIK 0001807901

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001818137

Filing Metadata

Form type
4
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 7:51 PM ET
Size
28.0 KB